34747-51-8

Basic information

• Product Name: AKOS BBS-00005699
• Synonyms: ASISCHEM C58428;AKOS BBS-00005699;N-(4,6-Dimethylpyrimidin-2-yl)-N'-(4-methylphenyl)guanidine;2-(4,6-dimethyl-2-pyrimidinyl)-1-(4-methylphenyl)guanidine;2-(4,6-dimethylpyrimidin-2-yl)-1-(4-methylphenyl)guanidine;BAS 00802056;MLS000564617;N-(4,6-Dimethyl-pyrimidin-2-yl)-N'-p-tolyl-guanidine
• CAS NO: 34747-51-8
• Molecular Formula: C₁₄H₁₇N₅
• Molecular Weight: 255.32
• Mol File: 34747-51-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AKOS BBS-00005699(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BBS-00005699(34747-51-8)
• EPA Substance Registry System: AKOS BBS-00005699(34747-51-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 34747-51-8(Hazardous Substances Data)

Upstream product

• 123-54-6 acetylacetone 
• 55474-90-3 (4,6-dimethylpyrimidin-2-yl)cyanamide 
• 540-23-8 p-toluidine hydrochloride 

Downstream Products

• 1070270-55-1 (E)-methyl 2-{(E)-2-[(4,6-dimethylpyrimidin-2-yl)imino]-5-oxo-3-p-tolylimidazolidin-4-ylidene}acetate 
• 1314895-29-8 2-[(4,6-dimethylpyrimidin-2-yl)imino]-1-p-tolylimidazolidin-4-one 

Relevant articles and documents

HETEROARYL GUANIDINES ; INHIBITORS OF VIRAL REPLICATION

Compounds of Formula (1), and pharmaceutically acceptable forms thereof, are provided wherein the variables X, Y, Z, Al, R2, R3, R4, R5 and R6 are defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula (1) that are potent and/ or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula (1), or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula (1) effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula (1) as a single active agent or administering a compound of Formula (1) in combination with on or more other therapeutic agent.

Condensation of isatoic anhydride with hetarylguanidines

Condensation of isatoic anhydride with 4-methylquinazolin-2-yl-, 2-benzoxazolyl-, 2-benzothiazolyl-, and 4,6-dimethylpyrimidin-2-ylguanidines leads to the corresponding 2-hetarylamino-4-hydroxy-quinazolines as a result of cyclization of intermediate anthranilic acid hetarylguanidides. These intermediates can be isolated as individual compounds.